Promoter methylation of transient receptor potential melastatin-related 7 (TRPM7) predicts a better prognosis in patients with Luminal A breast cancers

Table 6 Prognostic value of clinicopathological factors and TRPM7 methylation using univariate Cox regression analysis in different subtypes of breast cancers

Characteristics	Basal like		Her2 positive		Luminal A		Luminal B
Characteristics	HR^a (95% CI)	P	HR^a (95% CI)	P	HR^a (95% CI)	P	HR^a (95% CI)	P
TRPM7 methylation	0.69 (0.20–2.45)	0.57	0.53 (0.05–5.88)	0.61	0.26 (0.06–1.18)	0.08	0.58 (0.18–1.94)	0.38
Age^b	1.20 (0.74–1.93)	0.46	1.56 (0.63–3.85)	0.34	0.98 (0.62–1.55)	0.94	1.04 (0.69–1.58)	0.85
WHO grade^c	0.89 (0.21–3.79)	0.88	1.22 (0.13–11.47)	0.86	0.53 (0.14–2.05)	0.36	2.29 (0.73–7.20)	0.16
LNM^d	2.63 (0.76–9.09)	0.13	4.65 (0.42–52.04)	0.21	0.65 (0.18–2.39)	0.52	0.88 (0.27–2.94)	0.84
Endocrine therapy	/	/	/	/	0.45 (0.15–1.33)	0.15	0.60 (0.19–1.87)	0.38
Radiotherapy	/	/	3.77 (0.34–41.71)	0.28	0.50 (0.14–1.83)	0.29	1.28 (0.41–3.98)	0.66
Chemotherapy	0.84 (0.11–6.68)	0.87	/	/	1.65 (0.36–7.48)	0.52	1.63 (0.21–12.61)	0.64

^aHR: hazard ratio with 95% confidence interval (CI); ^bAge (per 10 years); ^cWHO grade (I, II, III and IV); ^dLymph node metastasis

ISSN: 1471-2407